Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04217746 · ClinicalTrials.gov registry record · NA
Effects of High Flow Nasal Cannula on Sputum Clearance in Acute Exacerbation of Chronic Obstructive Pulmonary Disease
A NA study, sponsored by Tufts Medical Center.
- Terminated
- Registry status
- NA
- Development phase
- 40
- Enrollment target
NCT04217746 is a NA study that was terminated before completion, run by Tufts Medical Center. The registered enrollment target is 40 participants.
The verdict
NCT04217746, a NA study, was terminated before completion, sponsored by Tufts Medical Center.
- TERMINATED
- Registry status
- NA
- Development phase
- 40 participants
- Enrollment target
Study Summary
Acute exacerbation of COPD usually presents with more sputum production leading to worsening airflow obstruction. Often patients complain of sensation of sputum (phlegm) stuck in throat, which leads to worsening cough and respiratory distress. In an acute exacerbation setting high flow nasal cannula (HFNC), which is a modality that provides humidified and warm oxygenated air at flow of upto 60L/min, has shown to reduce blood carbon dioxide level and respiratory rate. However, studies investigating other effects of HFNC in this setting are lacking. To investigators' knowledge, this is the first study investigating effects of HFNC on sputum clearance in COPD patients. The purpose of the study is to determine the effects of HFNC on sputum clearance in acute exacerbation of COPD. Primary objective of the study is to determine whether HFNC improves clearability and wettability of sputum produced during acute exacerbation of COPD. Secondary objectives of the study include subjective assessment of cough severity as well as need for escalation of care after HFNC use versus conventional flow nasal oxygen (CFNO) use.
Interventions
- DEVICE High Flow Nasal Cannula
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2020-02-01 |
| Est. Completion | 2025-02-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04217746
The ClinicalTrials.gov registry entry for NCT04217746 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tufts Medical Center, which has 169 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which High Flow Nasal Cannula is the first listed.
NCT04217746 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04217746 about?
NCT04217746 is a clinical study titled "Effects of High Flow Nasal Cannula on Sputum Clearance in Acute Exacerbation of Chronic Obstructive Pulmonary Disease". Acute exacerbation of COPD usually presents with more sputum production leading to worsening airflow obstruction. Often patients complain of sensation of sputum (phlegm) stuck in throat, which leads to worsening cough and respiratory distress. In an acute exacerbation setting high flow nasal cannula...
What is the current status of trial NCT04217746?
This trial is currently terminated. It is a NA study. The enrollment target is 40 participants. The study started on 2020-02-01. Estimated completion is 2025-02-01.
What interventions are being tested in trial NCT04217746?
The interventions under investigation include: High Flow Nasal Cannula (DEVICE).
Who is sponsoring clinical trial NCT04217746?
This trial is sponsored by Tufts Medical Center, which has 169 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.